Perlara
YC W16San Francisco, US · Founded 2014 · Delaware corporation · 1 employees · 1 known investors
Perlara is a biopharmaceutical company that develops treatments for ultra-rare genetic diseases using yeast-based disease modeling and drug repurposing strategies. The company operates as a full-stack drug development platform serving rare disease patients and families.
Also known as Perlstein Lab PBC
Founders & leadership· Y Combinator alumni (W16)
Perlara was founded in 2014 by Ethan Perlstein.
EP
Ethan PerlsteinCEO and founder
EO
Ethan O PerlsteinNamed on SEC filing
Board
MW
Matthew WilseyBoard director
LA
Linda AveyBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.9M disclosed across 2 rounds · 2014–2017
▶$4.1MraisedAug 2017 · 21 investors · BiotechnologyRule 506(b)
▶$4.1MraisedAug 2017 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ethan O PerlsteinExecutive Officer, Director, Promoter
- Matthew WilseyDirector
- Linda AveyDirector
- Offering amount
- $7.4M
- Amount sold
- $4.1M
- First sale
- Aug 2017
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$800KraisedMay 2014 · 2 investors · BiotechnologyRule 506(b)
▶$800KraisedMay 2014 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ethan O PerlsteinExecutive Officer, Director, Promoter
- Offering amount
- $2M
- Amount sold
- $800K
- First sale
- Apr 2014
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
The YC application· Winter 2016 batch
Competitors · 3
by search overlap
Pearl Bio4 shared keywordsPearl Bio develops technologies for genome engineering, ribosome engineering, and biomanufacturing to enable production of novel proteins, chemicals, and materials for biotechnology and medicine.
Palvellatx4 shared keywordsPalvella Therapeutics is a biotechnology company developing topical treatments for rare genetic skin diseases that lack approved therapies, based on its QTORIN drug delivery platform. Its lead candidate, QTORIN rapamycin gel, is in clinical development for microcystic lymphatic malformations and other mTOR-driven dermatologic conditions.
Pyrls4 shared keywordsPyrls provides a website and mobile application that helps clinicians prescribe medications, dispense them, and inform patients about their treatment regimens. The platform serves healthcare providers and medical trainees across numerous health systems.
Companies competing with Perlara for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Perlara do?
- Perlara is a biopharmaceutical company that develops treatments for ultra-rare genetic diseases using yeast-based disease modeling and drug repurposing strategies. The company operates as a full-stack drug development platform serving rare disease patients and families.
- Who founded Perlara?
- Perlara was founded by Ethan Perlstein in 2014.
- Who are Perlara's investors?
- Perlara's investors include Y Combinator.
- How much funding has Perlara raised?
- Perlara has disclosed $4.9M raised across 2 rounds.
- Where is Perlara headquartered?
- Perlara is headquartered in San Francisco, US.